Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | GCLC | P48506 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618202 | 1.00 | SLC22A6 (0.37) | SLC22A6GCLCNOS2BLMLMNA | |
| SCHEMBL30197101 | 0.83 | SLC22A6 (0.33) | SLC22A6GCLC | |
| Butyric Acid SCHEMBL25413135 | 0.82 | FFAR3 (0.46) | SLC22A6GCLCALOX15KMT2A | |
| SCHEMBL10332909 | 0.79 | GCLC (0.34) | GCLCNOS2BLMPMP22ALOX15 | |
| SCHEMBL1395227 | 0.79 | PTGS1 (0.46) | GCLCNOS2BLMPMP22ALOX15 | |
| SCHEMBL30600100 | 0.79 | PTGS1 (0.46) | GCLCNOS2BLMPMP22ALOX15 | |
| SCHEMBL44030 | 0.79 | PTGS1 (0.46) | GCLCNOS2BLMPMP22ALOX15 | |
| SCHEMBL44031 | 0.79 | PTGS1 (0.46) | GCLCNOS2BLMPMP22ALOX15 | |
| SCHEMBL21518548 | 0.79 | PTGS1 (0.46) | GCLCNOS2BLMPMP22ALOX15 | |
| SCHEMBL180559 | 0.79 | PTGS1 (0.46) | GCLCNOS2BLMPMP22ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 666 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611439-B2 | Ionic self-assembling peptides | 3-D MATRIX, LTD. (JP) | 2026-04-28 | — | — | US | claimed |
| US-20260027179-A1 | ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-01-29 | — | — | US | claimed |
| US-20250302963-A1 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULES | AADIGEN, LLC | 2025-10-02 | — | — | US | claimed |
| US-12428447-B2 | Peptide-based non-proteinaceous cargo delivery | FELDAN BIO INC. (CA) | 2025-09-30 | — | — | US | claimed |
| US-20250257342-A1 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF GENOME-EDITING MOLECULES | AADIGEN, LLC | 2025-08-14 | — | — | US | claimed |
| US-12357695-B2 | Peptides and nanoparticles for intracellular delivery of molecules | AADIGEN, LLC (US) | 2025-07-15 | — | — | US | claimed |
| US-20250161241-A1 | CYSTEAMIDES, THERAPEUTIC COMPOSITIONS THEREOF, AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2025-05-22 | — | — | US | claimed |
| WO-2025038979-A1 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND/OR TREATMENT OF AMYLOID B PEPTIDE PROTEINOPENIA IN ALZHEIMER'S AND OTHER DISEASES | LVIS-Regain LP (US) | 2025-02-20 | — | — | WO | claimed |
| EP-4486318-A2 | CYSTEAMIDES, THERAPEUTIC COMPOSITIONS THEREOF, AND RELATED METHODS | Boyce Thompson Institute for Plant Research Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-117736266-A | Preparation method and application of fibroblast activation protein specific diagnosis and treatment integrated probe | 上海交通大学医学院附属仁济医院 | 2024-03-22 | — | — | CN | claimed |
| US-20090292003-A1 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-11-26 | — | — | US | claimed |
| US-20090258926-A1 | Methods and Compositions for Delivering siRNA into Mammalian Cells | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-10-15 | — | — | US | claimed |
| US-20090156503-A1 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENT (FR) | 2009-06-18 | — | — | US | claimed |
| WO-2009046220-A2 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | MDRNA, INC. (US) | 2009-04-09 | — | — | WO | claimed |
| EP-1969000-A2 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES | Centre National de la Recherche Scientifique (FR) | 2008-09-17 | — | — | EP | claimed |
| WO-2007069090-A2 | CELL PENETRATING PEPTIDES FOR INTRACELLULAR DELIVERY OF MOLECULES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-06-21 | — | — | WO | claimed |
| EP-1795539-A1 | Cell penetrating peptides for intracellular delivery of molecules | Centre National de la Recherche Scientifique (FR) | 2007-06-13 | — | — | EP | claimed |
| US-20070129305-A1 | Cell penetrating peptides for intracellular delivery of molecules | CENTRE NATIONAL DE LA RECHERCHE SCIENT. (FR) | 2007-06-07 | — | — | US | claimed |
| US-20050239687-A1 | Complex comprising transfecting peptide vector and short interferring RNA, used as medicaments, in human and veterinary medicine, in human and animal gene therapy, in particular in hereditary diseases, as antiviral agents, as anticarcinogenic agents and inhibitors of gene overexpression | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE | 2005-10-27 | — | — | US | claimed |
| US-5350841-A | Amide derivatives of gangliocides including aminoacids or amino sulfonic acids for nervous system disorders | FIDIA S.P.A. (IT) | 1994-09-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027179-A1 | ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | SNCA, PARK7, LRRK2 | SLC22A6 3959/4885GCLC 1186/4885NOS2 4090/4885 |
| US-20250161241-A1 | CYSTEAMIDES, THERAPEUTIC COMPOSITIONS THEREOF, AND RELATED METHODS | CTH, CYSLTR2, LNPEP | SLC22A6 885/4885GCLC 26/4885NOS2 1715/4885 |
| US-12611439-B2 | Ionic self-assembling peptides | QPCTL, GLUL, VIP | SLC22A6 1224/4885GCLC 256/4885NOS2 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.